Silagy C, Neil A
Department of Public Health and Primary Care, University of Oxford.
J R Coll Physicians Lond. 1994 Jan-Feb;28(1):39-45.
Garlic supplements may have an important role to play in the treatment of hypercholesterolaemia. To determine the effect of garlic on serum lipids and lipoproteins relative to placebo and other lipid lowering agents, a systematic review, including meta-analysis, was undertaken of published and unpublished randomised controlled trials of garlic preparations of at least four weeks' duration. Studies were identified by a search of MEDLINE and the ALTERNATIVE MEDICINE electronic databases, from references listed in primary and review articles, and through direct contact with garlic manufacturers. Sixteen trials, with data from 952 subjects, were included in the analyses. Many of the trials had methodological shortcomings. The pooled mean difference in the absolute change (from baseline to final measurement in mmol/l) of total serum cholesterol, triglycerides, and high-density lipoprotein (HDL)-cholesterol was compared between subjects treated with garlic therapy against those treated with placebo or other agents. The mean difference in reduction of total cholesterol between garlic-treated subjects and those receiving placebo (or avoiding garlic in their diet) was -0.77 mmol/l (95% CI: -0.65, -0.89 mmol/l). These changes represent a 12% reduction with garlic therapy beyond the final levels achieved with placebo alone. The reduction was evident after one month of therapy and persisted for at least six months. In the dried garlic powders, in which the allicin content is standardised, there was no significant difference in the size of the reduction across the dose range of 600-900 mg daily. Dried garlic powder preparations also significantly lowered serum triglyceride by 0.31 mmol/l compared to placebo (95% CI: -0.14, -0.49).(ABSTRACT TRUNCATED AT 250 WORDS)
大蒜补充剂在高胆固醇血症的治疗中可能发挥重要作用。为了确定大蒜相对于安慰剂和其他降脂药物对血清脂质和脂蛋白的影响,我们进行了一项系统评价,包括荟萃分析,纳入了已发表和未发表的、持续时间至少四周的大蒜制剂随机对照试验。通过检索MEDLINE和替代医学电子数据库、参考原始文章和综述文章中列出的参考文献以及直接联系大蒜制造商来识别研究。分析纳入了16项试验,涉及952名受试者的数据。许多试验存在方法学缺陷。比较了接受大蒜治疗的受试者与接受安慰剂或其他药物治疗的受试者在总血清胆固醇、甘油三酯和高密度脂蛋白(HDL)胆固醇的绝对变化(从基线到最终测量值,单位为mmol/l)方面的合并平均差异。大蒜治疗组受试者与接受安慰剂(或在饮食中避免食用大蒜)组受试者相比,总胆固醇降低的平均差异为-0.77 mmol/l(95%置信区间:-0.65,-0.89 mmol/l)。这些变化表明,与仅使用安慰剂最终达到的水平相比,大蒜治疗可使胆固醇降低12%。治疗一个月后这种降低就很明显,并持续至少六个月。在蒜素含量标准化的干蒜粉中,每日剂量范围为600 - 900毫克时,降低幅度没有显著差异。与安慰剂相比,干蒜粉制剂还可使血清甘油三酯显著降低0.31 mmol/l(95%置信区间:-0.14,-0.49)。(摘要截取自250字)